Menopause Hair Loss Treatment: What the Evidence Actually Supports

The short answer

The single most useful thing to sort out before treating anything is which problem you actually have. Female pattern hair loss is a slow miniaturization process — the hairs get finer, not just fewer. Telogen effluvium is a diffuse shed that starts abruptly, sheds hairs of normal thickness from the whole scalp, and is triggered by something that happened months earlier: illness, surgery, a crash diet, childbirth, a new medication, severe stress. The two feel similar to the person experiencing them and are treated completely differently. Thyroid disease, iron deficiency, and a long list of medications can produce or worsen either one, and none of them respond to minoxidil.

Timing matters more here than in most cosmetic concerns. Follicles that have fully miniaturized are far harder to recover than ones still in the process, and a separate category of hair loss — the scarring alopecias — destroys follicles permanently, so any scalp pain, burning, redness, scaling, or smooth patches without visible pores is a reason to be seen quickly rather than to run a self-treatment experiment. Everything below is information, not medical advice, and nothing here is a prescription or a recommendation to start any drug.

What actually changes in hair around menopause

Hair follicles cycle through a growth phase (anagen), a brief transitional phase, and a resting phase (telogen) that ends with the hair being shed. The length of the growth phase determines how long a hair can get, and the diameter of the follicle determines how thick it is. In female pattern hair loss, susceptible follicles on the top of the scalp progressively shorten their growth phase and shrink in diameter with each cycle. That process is called miniaturization. A hair that was once thick and long is replaced by a shorter, finer one, and eventually by something closer to peach fuzz. The follicle is not dead; it is producing a smaller product.

Two things converge around the menopause transition. Ovarian estrogen production falls substantially, while adrenal and ovarian androgen production declines much more gradually with age. The result is a shift in the relative hormonal environment at the follicle. Estrogen appears to favor a longer growth phase, so its withdrawal alone can shorten anagen. At the same time, follicles on the crown that carry androgen sensitivity are now operating with less estrogenic counterbalance. This is why a genetic tendency that produced no visible thinning earlier in life can become obvious after the transition.

The Stages of Reproductive Aging Workshop +10 staging system, summarized in the Journal of Clinical Endocrinology and Metabolism in 2012, describes this transition in terms of menstrual cycle changes and hormonal markers rather than symptoms. It is worth knowing that the endocrine shift is a process spanning years, not an event. Hair changes generally track that gradual arc rather than appearing overnight — which is itself a diagnostic clue, since an overnight change points elsewhere.

Importantly, most women with female pattern hair loss do not have an androgen excess disorder. Testosterone levels are typically normal. The sensitivity of the follicle, not the circulating level of the hormone, is usually what differs. That matters clinically because it means normal blood work does not rule out pattern hair loss, and it means that lowering hormone levels is not automatically the fix.

Female pattern hair loss vs telogen effluvium: how to tell them apart

This distinction determines everything downstream. Telogen effluvium is a shift of many follicles into the resting phase at once, followed by a synchronized shed some months later. The hairs that come out are full-caliber, the loss is diffuse across the whole scalp rather than concentrated on the crown, and the volume of shedding is dramatic — visible on the pillow, in the shower drain, on clothing. Because it is a cycling problem rather than a miniaturization problem, telogen effluvium is generally self-limited once the trigger is removed, and hair density recovers.

Female pattern hair loss produces much less dramatic day-to-day shedding but a steady loss of coverage. The classic signs are a part line that gets wider toward the front, scalp becoming visible under direct overhead light, and a ponytail circumference that has shrunk over years. Hairs of visibly different thicknesses growing side by side is the hallmark of miniaturization and is something a dermatologist looks for directly with a dermatoscope.

The two conditions frequently coexist. A woman with underlying pattern hair loss who then has a surgery, a severe illness, or a rapid weight loss can develop an effluvium on top of it — and the effluvium unmasks thinning that was previously camouflaged. When that happens, the shed resolves but the density does not return to what she remembers, because the pattern component was always there.

One practical test you can do at home is the ponytail comparison: measure the circumference of a gathered ponytail with a soft tape and record it with the date. Repeated at intervals, that single number is more informative than daily impressions, which are heavily influenced by lighting, mood, and how recently you washed.

Causes that must be ruled out before blaming menopause

Thyroid disease is the first to exclude. Both underactive and overactive thyroid can cause diffuse hair thinning, and both are common in women in midlife. Thyroid symptoms overlap heavily with menopause symptoms — fatigue, weight change, temperature intolerance, mood change — so the clinical picture alone will not sort it out. A TSH is a cheap, decisive test.

Iron deficiency is the second. It is possible to be iron-deficient without being anemic, so a normal hemoglobin does not settle the question; ferritin is the marker that reflects iron stores. Women who are still cycling with heavy periods during perimenopause are at particular risk, and heavy perimenopausal bleeding is itself something ACOG advises evaluating rather than assuming is normal. Correcting iron deficiency will not treat pattern hair loss, but leaving it uncorrected undermines any treatment you layer on top.

Medications are the third and the most commonly missed. Whole drug classes are associated with hair shedding, and the delay between starting a drug and noticing the shed makes the connection easy to overlook. Rather than stopping anything yourself, bring a complete list of everything you take — prescriptions, over-the-counter items, supplements — to the appointment and ask directly whether any of it could contribute.

Beyond these, sudden or severe caloric restriction, protein inadequacy, recent major illness or surgery, and new autoimmune conditions all belong on the list. Scarring alopecias — where the follicle is permanently destroyed and replaced by fibrous tissue — are a separate and urgent category, because in those conditions time lost is follicles lost permanently. Scalp pain, burning, itching, redness, scaling, or smooth shiny patches with no visible follicular openings should prompt a prompt dermatology visit rather than a trial of an over-the-counter product.

What a dermatologist actually does at the visit

A hair loss consultation is more than looking at the scalp from across the room. The examination typically includes parting the hair in several locations to compare density at the crown against density at the back of the head, since the occipital scalp is generally spared in pattern hair loss and serves as an internal control. A dermatoscope magnifies the scalp enough to show variability in hair shaft diameter, the number of hairs emerging from each follicular unit, and whether follicular openings are still present.

A pull test — gently grasping a small bundle of hairs and applying steady traction — gives a rough sense of how many hairs are in the shedding phase. A markedly positive pull test across multiple scalp regions points toward an effluvium; a pull test that is positive only at the crown is more consistent with active pattern loss. Standardized photography at the first visit is genuinely valuable, because months later memory is unreliable and side-by-side images are not.

Blood work is usually targeted rather than exhaustive: thyroid function and iron studies at minimum. Androgen testing is not routine for typical female pattern hair loss with normal periods and no other signs, but it becomes relevant when hair loss is rapid, or when it comes with new facial hair growth, acne, deepening voice, or menstrual irregularity that does not fit the expected perimenopausal picture.

In a minority of cases, particularly where a scarring alopecia is suspected or the picture is atypical, a scalp biopsy is taken. It is a small punch of skin done under local anesthetic, and it can distinguish scarring from non-scarring processes definitively when the clinical exam cannot.

Topical minoxidil: what the trial evidence supports

Topical minoxidil is the treatment with the most direct randomized evidence in women. The 2004 trial in the Journal of the American Academy of Dermatology was a randomized, placebo-controlled comparison of 5% and 2% topical minoxidil in female pattern hair loss — meaning both active strengths were tested against a vehicle control in the population this page is about, rather than extrapolated from studies in men. That design is what makes it the reference point.

Mechanistically, minoxidil appears to prolong the growth phase and increase follicle size, which is why it is well matched to a miniaturization problem and poorly matched to a shedding problem with an external trigger. It does not lower androgens and does not address estrogen withdrawal directly. It acts on the follicle itself.

Two practical points shape whether it works in real life. First, it is applied to the scalp, not to the hair — parting the hair and delivering it to the skin is the part people get wrong. Second, it is a maintenance treatment. Follicles that respond do so as long as the drug continues, and stopping typically means the gains are lost over the following months. Anyone starting it should understand up front that this is an ongoing commitment rather than a course of treatment.

An increase in shedding during the first weeks of use is a well-described and expected phenomenon: existing resting hairs are pushed out as follicles are driven back into the growth phase. It is the most common reason people quit before the treatment has had a chance to show anything. Local irritation, itching, and scaling are the usual side effects, and unwanted hair growth on the face can occur if the product migrates — washing hands after application and letting the scalp dry before lying down reduces that.

Formulation matters for tolerability more than for potency. Alcohol-and-propylene-glycol solutions cause more irritation for many women than foam preparations, which is a legitimate reason to switch if the first attempt is intolerable. Which strength, which formulation, and how often to apply it are clinical decisions, and the strength-versus-tolerability trade-off is exactly the conversation to have with a dermatologist rather than resolve in a pharmacy aisle.

Low-dose oral minoxidil: what the newer literature shows

Oral minoxidil was originally a blood pressure drug, and excessive hair growth was one of its notable side effects. Dermatology has since examined whether much smaller oral doses — far below antihypertensive dosing — can be used deliberately for hair loss. A review of the efficacy and safety of oral minoxidil for hair loss was published in the Journal of the American Academy of Dermatology in 2021, and a study specifically examining low-dose oral minoxidil for female pattern hair loss appeared in Skin Appendage Disorders in 2020.

What these publications establish is that low-dose oral minoxidil has been studied in this population with reported benefit and a characterized side-effect profile. What they do not establish is head-to-head superiority over topical minoxidil, or a settled place in a treatment sequence. Oral minoxidil for hair loss is off-label. It requires a prescription and a clinician who is willing to monitor it.

The practical appeal is adherence and delivery. A tablet avoids the scalp irritation, the greasy residue, the interference with styling, and the repeated application routine that cause many women to abandon topical treatment. For women with dense hair that makes scalp application awkward, or with contact dermatitis from the vehicle, the oral route removes the specific obstacle that caused failure.

The trade-off is that the drug now acts systemically. Hypertrichosis — hair growth in places you did not want it, commonly the face, forearms, and trunk — is the most frequently reported adverse effect and is dose-related. Fluid retention, ankle swelling, and lightheadedness can occur because of the drug's vasodilatory action. Pericardial effusion has been described with minoxidil, which is why a cardiac history, existing heart failure, or use of other blood-pressure-lowering drugs changes the risk calculation substantially. This is a drug that belongs under supervision, with a baseline discussion about cardiovascular history, and it is not appropriate to source it outside a prescribing relationship.

Where spironolactone fits

Spironolactone is a potassium-sparing diuretic that also blocks androgen receptors, and dermatologists use it off-label for female pattern hair loss on that anti-androgen basis. The logic is straightforward: if crown follicles are miniaturizing partly because of androgen sensitivity in a lower-estrogen environment, blunting androgen signaling at the receptor addresses a different step in the process than minoxidil does. In practice it is used either alone or alongside topical treatment.

It is prescription-only and comes with real constraints. Potassium can rise, so kidney function and potassium are checked and the drug interacts with other agents that raise potassium, including certain blood pressure medications and potassium supplements. Blood pressure can drop. Breast tenderness and menstrual irregularity are reported. Spironolactone is not used in pregnancy because of the potential for feminization of a male fetus, which matters for anyone in perimenopause who is still capable of conceiving and who should therefore have a contraception conversation as part of the prescribing decision.

Because spironolactone is not on the verified source list for this page, no efficacy numbers are quoted here. What can be said accurately is that it is an established off-label option in dermatology practice with a mechanism distinct from minoxidil's, and that the decision to use it is a clinical one that depends on kidney function, potassium, blood pressure, other medications, and pregnancy potential. If it comes up in your appointment, those are the specific items to work through.

What hormone therapy does and does not do for hair

The 2022 hormone therapy position statement of The North American Menopause Society, published in Menopause, frames hormone therapy around the indications it is prescribed for: bothersome vasomotor symptoms, genitourinary syndrome of menopause, and prevention of bone loss, with the benefit-risk balance most favorable for healthy women who are under 60 or within 10 years of their final menstrual period. Hair growth is not one of the indications. Nobody should be prescribed systemic hormone therapy for hair.

That said, the honest answer to "will HT help my hair?" is that it might have some indirect effect and might have none, and it is not predictable enough to be a plan. Restoring estrogen exposure plausibly influences the follicle growth phase, and some women on hormone therapy notice their hair feels better. But it is equally common to notice nothing, and the treatment carries its own risk profile that has to be justified by the indications above. Deciding to take hormone therapy because of hair is putting a large decision on a small and uncertain expected benefit.

There is a related and more concrete point: the progestogen component matters. Progestogens differ in their androgenic activity, and for a woman with a uterus who needs endometrial protection alongside estrogen, which progestogen she is on is a reasonable thing to raise if hair thinning is a significant concern for her. That is a question to put to the prescriber, not something to self-adjust.

Compounded bioidentical hormone preparations deserve a specific caution here, because they are marketed heavily for symptoms including hair and skin changes. ACOG's 2023 clinical consensus on compounded bioidentical menopausal hormone therapy and the National Academies report on the clinical utility of compounded bioidentical hormone therapy both address the concerns with these products. Salivary hormone testing followed by a custom-compounded cream sold as a hair and skin solution is not an evidence-based pathway.

Comparing the main options at a glance

No single option is right for everyone, and the choice depends on how much thinning there is, how it is affecting you, what other conditions and medications are in play, and what you will realistically keep doing. The table below summarizes what is on the table and on what basis.

One thing all effective options share is that they are maintenance treatments. There is no course of treatment that fixes pattern hair loss and then ends. Understanding that before starting prevents the common cycle of starting, stopping, losing the ground that was gained, and starting over.

Realistic expectations about time and how to measure progress

Hair grows slowly, and any treatment that works does so by changing what the follicle produces on its next cycle. That is a biological constraint no product can shortcut. The consequence is that assessing a hair treatment requires many months of consistent use, not weeks, and that the first visible change is often the absence of further deterioration rather than obvious regrowth. If you judge it after a few weeks you will conclude it failed regardless of whether it worked.

The trajectory that many people experience is a period of increased shedding early on, followed by a plateau where nothing seems to be happening, followed by a gradual change in the texture and density of new growth that is easier to see in photographs than in the mirror. Because the first phase looks exactly like the treatment making things worse, it is where most people quit.

Measure rather than trust impressions. Take a photograph at the same part line, in the same room, with the same lighting, at the same time of day, at baseline and then at set intervals. Record ponytail circumference with a tape measure. Note the date you started and any change in products. These three data points cost nothing and turn a subjective and emotionally loaded question into something you can actually answer at the next appointment.

Set the goal correctly, too. For most women with established pattern hair loss the realistic outcome is stabilization plus some improvement in density, not a return to the hair they had before it started thinning. Treatments that promise the latter are selling something. A treatment that stops a progressive process is a genuine success even when the mirror looks similar to last year.

Cosmetic and everyday measures that genuinely help

None of these change the biology, and none should replace evaluating a treatable cause. But they change how visible thinning is, and that is often what the distress is actually about. Volumizing products and lighter conditioning formulas at the roots make fine hair read as fuller. Shorter and layered cuts create the appearance of density that long, fine hair works against, because weight pulls hair flat against the scalp and exposes the part.

Scalp-colored powders and fibers reduce contrast between the scalp and the hair, which is what makes a widening part conspicuous. Moving the part line to a less-thinned area is free and immediately effective. For women who color their hair, going slightly lighter reduces the scalp-to-hair contrast for the same reason.

Traction matters over years. Tight ponytails, tight braids, and heavy extensions apply sustained tension at the hairline and can cause traction alopecia, which is a separate and potentially permanent form of loss layered on top of everything else. Repeated high heat and chemical processing damage the hair shaft, causing breakage that reads as thinning even when follicle density is unchanged — breakage produces short broken ends of varying length, which is a distinguishable finding.

Washing frequency is a persistent myth worth retiring. Washing does not cause hair loss. The hairs that come out in the shower were already shed and are simply being released; washing less often just batches them into a more alarming clump on the next wash. Avoiding washing to reduce apparent shedding is not protective.

When to see a dermatologist rather than wait

Waiting has a cost in pattern hair loss because the follicles that have fully miniaturized are much harder to bring back than the ones still in the process. That alone is a reasonable argument for an early visit rather than a prolonged self-treatment experiment. But there are specific circumstances where the visit should not be optional.

Rapid loss — a substantial change over weeks rather than years — is not typical pattern hair loss and needs evaluation. Loss in discrete round patches suggests alopecia areata rather than pattern hair loss. Any scalp symptoms, meaning pain, burning, persistent itching, tenderness, redness, or scaling, raise the possibility of an inflammatory or scarring process where the delay is what causes the permanent damage. Areas where the scalp looks smooth and shiny with no visible pores are a specific concern for scarring alopecia.

Hair loss with other signs of androgen excess — new coarse facial hair, new adult acne, voice deepening — points toward a different evaluation entirely. Hair loss alongside heavy or irregular bleeding warrants attention to both, and ACOG advises that bleeding after menopause is always evaluated rather than attributed to the transition.

If you are seeing a clinician about this, a board-certified dermatologist with an interest in hair disorders will get further than a general visit, because the diagnosis rests on examination findings that require dermoscopy and pattern recognition. Bring your photographs, your medication list including supplements, and the date the change started.

What this page does not cover

Several treatments circulate in this space that are outside what can be responsibly summarized here, because the verified evidence bank for this page does not include studies on them. Platelet-rich plasma injections, low-level laser devices, microneedling, topical anti-androgens, and hair transplantation in women are all discussed in dermatology literature; none of them are assessed on this page, and their absence here is not an endorsement or a dismissal. Ask a dermatologist what the evidence looks like for any of them in your specific situation.

Oral supplements marketed for hair deserve one general caution. Correcting a documented deficiency is a medical intervention with a rationale. Taking high-dose supplements without a documented deficiency is not, and some — notably excess vitamin A and excess selenium — are themselves associated with hair loss. Biotin supplementation can interfere with several common laboratory assays, including thyroid and cardiac tests, which can produce misleading results at exactly the moment you are being worked up. Tell any clinician ordering blood work what supplements you take.

This site is an information resource. It does not sell, prescribe, or dispense anything, and no product mentioned by category here is being recommended to you personally. Decisions about prescription treatments — including oral minoxidil and spironolactone — belong with a clinician who knows your history.

Questions to ask your clinician

Bring these to your appointment — they turn a vague visit into a decision.

• Based on how my scalp looks, is this female pattern hair loss, telogen effluvium, or both at the same time?
• Can you check my thyroid function and my ferritin, not just my hemoglobin?
• Here is everything I take, including supplements — could any of these be contributing to my hair loss?
• If I try topical minoxidil, which strength and formulation would you suggest for my scalp, and how long should I use it before we judge whether it worked?
• Am I a candidate for low-dose oral minoxidil, and does anything in my heart or blood pressure history make that a bad idea for me?
• Would spironolactone make sense in my case, and what would you need to monitor if I took it?
• Can we take standardized photographs today so we have a baseline to compare against at my next visit?

Frequently asked questions

Is hair loss at menopause permanent?

Female pattern hair loss is progressive if untreated, but the follicles are miniaturized rather than destroyed, which is why treatment can improve density. The exception is scarring alopecia, where follicles are replaced by fibrous tissue and the loss is permanent — that is why scalp pain, burning, redness, scaling, or smooth areas with no visible pores need prompt evaluation rather than a wait-and-see approach.

Will my hair grow back once menopause is over?

Pattern hair loss does not resolve on its own once the transition ends, because the underlying change is a shortened follicle growth phase and reduced follicle size rather than a temporary disturbance. Telogen effluvium, by contrast, does recover once the trigger is removed. This is the practical reason the two need to be distinguished before deciding whether to treat or wait.

Is 5% or 2% topical minoxidil better for women?

The 2004 randomized trial in the Journal of the American Academy of Dermatology compared both strengths against placebo in women with female pattern hair loss, which is why both are discussed for this population. Which strength suits a given woman depends on how her scalp tolerates it, since irritation is the main reason topical treatment gets abandoned. That trade-off is worth working through with a dermatologist.

Is low-dose oral minoxidil safe?

Oral minoxidil for hair loss is off-label and prescription-only, and its safety profile was reviewed in the Journal of the American Academy of Dermatology in 2021. The recognized issues are unwanted hair growth on the face and body, fluid retention and swelling, and lightheadedness from its vasodilatory action, with cardiac effects including pericardial effusion described for the drug. Existing heart disease or other blood-pressure-lowering medications change the risk calculation, so it needs supervision rather than self-sourcing.

Does hormone therapy help with hair loss?

Hair growth is not an indication for menopausal hormone therapy. The 2022 NAMS position statement frames hormone therapy around vasomotor symptoms, genitourinary syndrome of menopause, and bone loss prevention. Some women notice their hair seems better on it and many notice nothing; the effect is not predictable enough to justify the decision on that basis alone.

What blood tests should I ask for?

Thyroid function and iron studies including ferritin are the two that most often change management, because both conditions cause diffuse hair loss and both are common in midlife women. A normal hemoglobin does not exclude low iron stores, so ferritin specifically is worth naming. Androgen testing is not routine unless there is rapid loss, new coarse facial hair, new acne, voice change, or menstrual irregularity beyond what the transition explains.

Why did my hair start shedding heavily months after I was ill?

That delay is the signature of telogen effluvium. A physiological stressor pushes many follicles into the resting phase simultaneously, and the shed happens months later when those hairs release. The shed hairs are normal thickness and the loss is diffuse rather than concentrated on the crown. It is generally self-limited once the trigger has resolved.

Do I have to keep using minoxidil forever?

Minoxidil is a maintenance treatment. Follicles respond while it is being used, and the improvement is typically lost over the months after stopping, whether the route is topical or oral. Anyone starting should treat it as an ongoing commitment rather than a course, because the stop-start cycle wastes the months it takes to see any effect.

Can biotin or hair supplements help?

Correcting a documented deficiency is worthwhile; supplementing without one is not supported and can backfire, since excess vitamin A and excess selenium are themselves associated with hair loss. Biotin specifically can interfere with common laboratory assays including thyroid and cardiac tests, which risks producing misleading results during the exact workup you need. Tell any clinician ordering blood work what supplements you take.

How long before I know whether a treatment is working?

Assessment takes many months, not weeks, because change happens on the timescale of the hair cycle. An early increase in shedding is expected with minoxidil and is not evidence of failure. Standardized photographs at the same part line and lighting, plus ponytail circumference measurements taken at intervals, are far more reliable than day-to-day impressions.

Primary sources

1. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil in female pattern hair loss. J Am Acad Dermatol, 2004. PMID 15034503.
2. Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol, 2021. PMID 32622136.
3. Low-Dose Oral Minoxidil for Female Pattern Hair Loss. Skin Appendage Disord, 2020. PMID 32656239.
4. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022. PMID 35797481.
5. Executive summary of the Stages of Reproductive Aging Workshop +10. J Clin Endocrinol Metab, 2012. PMID 22344196.
6. Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus. Obstet Gynecol, 2023. PMID 37856860.
7. National Academies: The Clinical Utility of Compounded Bioidentical Hormone Therapy.
8. ACOG: Perimenopausal Bleeding and Bleeding After Menopause (patient FAQ).
9. ACOG: Heavy Menstrual Bleeding (patient FAQ).
10. Office on Women's Health: Menopause basics.